Medical Center Hera - Kyustendil EOOD

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Heart failure4 trials
• Obesity3 trials
• High blood pressure1 trial
• Type 2 diabetes1 trial

Phase

• Phase 37 trials
• Phase 21 trial

Status

• Recruiting5 trials
• Active, not recruiting3 trials

Lead sponsor

• Boehringer Ingelheim3 trials
• Kailera2 trials
• Novo Nordisk A/S2 trials
• Pfizer1 trial

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  NCT07284901· Phase 3· Kailera· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  NCT07284875· Phase 3· Kailera· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

  NCT06991257· Phase 2· Pfizer· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure3 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting